Rubius Therapeutics is hoping to raise $200m in an initial public offering (IPO) for its personalised red blood cell therapies. The company has raised $200m from investors including the venture capital firm Kleiner Perkins Caufield & Byers, and private equity firms Accel Partners and TPG Capital. It also said it aims to file an investigative new drug application in early 2019 and also has plans for extra RCT product candidates in the coming years.
Rubius Therapeutics is hoping to raise $200m in an initial public offering (IPO) for its personalised red blood cell therapies. In its filing with the US Securities and Exchange Commission, the company said it had generated hundreds of red cell therapies (RCT) through its Rubius Erythrocyte Design platform. It also said it aims to file an investigative new drug application in early 2019 and also has plans for extra RCT product candidates in the coming years.